Showing 31-40 of 3009 results for "".
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- Del-Desiran Misses Primary Endpoint in Phase 3 HARBOR Trial for Myotonic Dystrophy Type 1https://practicalneurology.com/news/del-desiran-misses-primary-endpoint-in-phase-3-harbor-trial-for-myotonic-dystrophy-type-1/2488477/KEY TAKEAWAYS Delpacibart etedesiran (del-desiran) did not significantly improve video hand opening time vs placebo in the phase 3 HARBOR trial of people with myotonic dystrophy type 1 (DM1). Del-desiran showed e
- New Titration Schedule for Kisunla/Donanemab Approved by FDAhttps://practicalneurology.com/news/new-titration-schedule-for-kisunladonanemab-approved-by-fda/2475633/The Food and Drug Administration (FDA) has approved a new titration dosing schedule for Kisunla (donanemab-azbt; Eli Lilly and Company, Indianapolis, IN), which is intended to lower the risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in the treatment of people with earl
- Rizatriptan Not Effective for Acute Vestibular Migraine Reliefhttps://practicalneurology.com/news/rizatriptan-not-effective-for-acute-vestibular-migraine-relief/2475105/Results from a randomized clinical trial published in JAMA Neurology found that treatment with rizatriptan was ineffective for managing acute symptoms of vestibular migraine but was modestly effective at controlling headache-related symptoms at 24 hours. This double-blind study e
- New Scholarship for Medical Students Interested in Neurology Establishedhttps://practicalneurology.com/news/new-scholarship-for-medical-students-interested-in-neurology-established/2470434/Ameer E. Hassan, DO, a professor of neurology at the University of Texas and a practicing neurologist at the Valley Baptist Medical Center-Harlingen, has established a new educational funding opportunity: the Dr. Ameer Hassan Scholarship for Medical Students. The scholarship consists of a one-tim
- Potassium Channel Modulator Reduces Focal Onset Seizure Frequency in Clinical Trialshttps://practicalneurology.com/news/potassium-channel-modulator-reduces-focal-onset-seizure-frequency-in-clinical-trials/2469954/In the phase 2b X-TOLE trial, participants ( treated with the positive allosteric modulator of the KCNQ2/3 (Kv7.2/7.3) potassium channel (XEN1101; Xenon Pharmaceuticals, Burnaby, British Columbia) had significant reduction in the frequency of focal onset seizures. Seizure reductions occurred as e
- Rapid and Sustained Seizure Termination With Midazolam in Open-Label Extension Studyhttps://practicalneurology.com/news/rapid-and-sustained-seizure-termination-with-midazolam-in-open-label-extension-study/2469769/Post hoc analysis of an open-label extension study (NCT01529034) showed treatment with midazolam nasal spray (Nayzilam; UCB Pharma, Smyrna, GA) terminated 92% of seizure cluster episodes. There was no seizure recurrence from 10 minutes of treatment to 24 hours for 85% of treated seizure cluster e
- Phase 2b Study Ending for Sublingual Ketamine for Acute Painhttps://practicalneurology.com/news/phase-2b-study-ending-for-sublingual-ketamine-for-acute-pain/2468909/The Food and Drug Administration (FDA) has scheduled an end-of-phase 2 clinical trial meeting for a sublingual formulation of racemic ketamine (Wafermine; iX Biopharma, Singapore) for treatment of moderate-to-severe acute pain. The therapy contains R and S isomers of ketamine in e
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie